Press Releases

Date Title and Summary Additional Formats
Toggle Summary Seattle Genetics Scheduled to Present at CIBC Healthcare Conference
Bothell, WA — November 1, 2001 — Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Scientific Officer, will speak at the CIBC World Markets Twelfth Annual Healthcare Conference on Tuesday, November 6, 2001 at 11:00 a.m. Eastern Time.
View HTML
Toggle Summary Seattle Genetics Reports Third Quarter 2001 Results
Bothell, WA — October 23, 2001— Seattle Genetics, Inc. (Nasdaq: SGEN) today reported results for its third quarter and nine months ended September 30, 2001. Revenues for the quarter were $70,000, compared to revenues of $27,000 in the third quarter of 2000.
View HTML
Toggle Summary Seattle Genetics Licenses Potent Cell-Killing Drugs from Proacta Therapeutics
Bothell, WA – October 22, 2001 – Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that they have entered into an agreement to license certain cell-killing drugs from Proacta Therapeutics, based in Auckland, New Zealand. Seattle Genetics intends to evaluate the highly potent, synthetic drugs as
View HTML
Toggle Summary Seattle Genetics Scheduled to Present at UBS Warburg Global Life Sciences Conference
Bothell, WA — October 5, 2001 — Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that H. Perry Fell, Ph.D., Chief Executive Officer, will speak at the UBS Warburg Global Life Sciences Conference on Tuesday, October 9, 2001 at 8:40 a.m. Eastern Time.
View HTML
Toggle Summary Seattle Genetics Scheduled at Raymond James Healthcare Conference
Bothell, WA — September 26, 2001 — Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that H. Perry Fell, Ph.D., Chief Executive Officer, will speak at the Raymond James & Associates Healthcare Conference on Monday, October 1, 2001 at 2:50 p.m. Central Time.
View HTML
Toggle Summary Seattle Genetics Awarded National Institutes of Health Funded Research Grant
Bothell, WA – September 19, 2001 – Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it was awarded a research grant by the National Institutes of Health (NIH) to support the Company’s development of monoclonal antibody-drug conjugates for the treatment of cancer.
View HTML
Toggle Summary Seattle Genetics Initiates Phase II Clinical Trial with SGN-15 in Lung Cancer
Bothell, WA – August 21, 2001 – Seattle Genetics, Inc. (Nasdaq: SGEN) announced the initiation of a phase II clinical trial for patients with non-small cell lung cancer with its product candidate, SGN-15, a monoclonal-antibody drug conjugate. The trial will evaluate SGN-15 in combination with the
View HTML
Toggle Summary Seattle Genetics Announces Business Update Meeting and Webcast
Bothell, WA — August 16, 2001 — Seattle Genetics, Inc. (Nasdaq: SGEN) company management will host a business update meeting on August 21, 2001 at approximately 3:45 p.m. Pacific Time. The session will include presentations on research, development and clinical trial activities.
View HTML
Toggle Summary Seattle Genetics Announces Relocation and Expansion of Corporate Headquarters
Bothell, WA – August 14, 2001 – Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that the Company has relocated its corporate office and laboratory space to a new, significantly larger facility, located a short distance from their former site in Bothell’s Canyon Park area.
View HTML
Toggle Summary Seattle Genetics Signs Development and Manufacturing Agreement with ICOS for the Monoclonal Antibody Component of SGN-15
Bothell, WA – August 14, 2001 – Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that the Company has entered into an agreement with ICOS Corporation (Nasdaq: ICOS) for the development and manufacture of the monoclonal antibody component of its lead antibody-drug conjugate SGN-15.
View HTML